Case report: Therapeutic response to lorlatinib in advanced large-cell neuroendocrine carcinoma of the lung and breast cancer: a heterochronous double malignancy perspective

This case suggested that ALK-positive advanced LCNEC patients might benefit from first-line intervention with lorlatinib, particularly for managing brain metastases.

Authors

Institutions

Publication Details

Journal
Frontiers in Pharmacology
Published
2024-12-10
DOI
https://doi.org/10.3389/fphar.2024.1413897
Citations
1
Primary Topic
Neuroendocrine Tumor Research Advances
Type
article
Field-Weighted Citation Impact
0.39

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Case report: Therapeutic response to lorlatinib in advanced large-cell neuroendocrine carcinoma of the lung and breast cancer: a heterochronous double malignancy perspective

Yan Li, Xiaoli Mu
1 citations
Frontiers in Pharmacology
Neuroendocrine Tumor Research Advances
0.39
article

Case report: Therapeutic response to lorlatinib in advanced large-cell neuroendocrine carcinoma of the lung and breast cancer: a heterochronous double malignancy perspective

Yan Li, Xiaoli Mu
article en
1 citations

Abstract

This case suggested that ALK-positive advanced LCNEC patients might benefit from first-line intervention with lorlatinib, particularly for managing brain metastases.

Frontiers in PharmacologyVol. 15
Sichuan University (CN)
Wu Jieping Medical Foundation
Good health and well-being
Openalex Percentile: Top 31%
Neuroendocrine Tumor Research Advances
0.39
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Case report: Therapeutic response to lorlatinib in advanced large-cell neuroendocrine carcinoma of the lung and breast cancer: a heterochronous double malignancy perspective — Yan Li, Xiaoli Mu · Frontiers in Pharmacology (2024) | TGRS Research Map | TGRS